Flupenthixol癸酸盐(仓库)精神分裂症或其他类似的精神障碍。

文章的细节

引用

复制到剪贴板

马哈J, Quraishi SN,大卫·桑普森,亚当斯CE

Flupenthixol癸酸盐(仓库)精神分裂症或其他类似的精神障碍。

科克伦数据库系统启2014 6月10;(6):CD001470。cd001470.pub2 doi: 10.1002/14651858.。

PubMed ID

24915451 (在PubMed

]

文摘

背景:长效注射的药物如flupenthixol癸酸酯广泛用作长期维持治疗精神分裂症的一种手段。目的:评价的影响flupenthixol癸酸盐与安慰剂相比,口服抗精神病药物和其他仓库安定精神分裂症患者的准备工作和其他严重的精神疾病,在临床方面,社会和经济的结果。搜索方法:我们确定了相关试验通过搜索Cochrane精神分裂症组试验注册这个更新版本,2009年3月,然后搜索运行于2013年4月。寄存器是基于定期搜索CINAHL、EMBASE, MEDLINE和PsycINFO。引用的识别研究为进一步试验检查。我们联系了相关的制药公司,药物审批机构和作者的试验附加信息。选择标准:所有专注于精神分裂症患者随机对照试验或其他类似的精神病flupenthixol癸酸盐与安慰剂比较或其他抗精神病药物包括在内。所获得的所有临床相关的结果。数据收集和分析:独立审查作者选择的研究,评估试验质量和提取数据。两个数据我们估计风险比率(RR)和95%可信区间(CI)使用固定效应模型。 Analysis was by intention-to-treat. We summated normal continuous data using mean difference (MD), and 95% CIs using a fixed-effect model. We presented scale data only for those tools that had attained prespecified levels of quality. Using Grading of Recommendations Assessment, Development and Evaluation (GRADE) we created 'Summary of findings tables and assessed risk of bias for included studies. MAIN RESULTS: The review currently includes 15 randomised controlled trials with 626 participants. No trials compared flupenthixol decanoate with placebo.One small study compared flupenthixol decanoate with an oral antipsychotic (penfluridol). Only two outcomes were reported with this single study, and it demonstrated no clear differences between the two preparations as regards leaving the study early (n = 60, 1 RCT, RR 3.00, CI 0.33 to 27.23,very low quality evidence) and requiring anticholinergic medication (1 RCT, n = 60, RR 1.19, CI 0.77 to 1.83, very low quality evidence).Ten studies in total compared flupenthixol decanoate with other depot preparations, though not all studies reported on all outcomes of interest. There were no significant differences between depots for outcomes such as relapse at medium term (n = 221, 5 RCTs, RR 1.30, CI 0.87 to 1.93, low quality evidence), and no clinical improvement at short term (n = 36, 1 RCT, RR 0.67, CI 0.36 to 1.23, low quality evidence). There was no difference in numbers of participants leaving the study early at short/medium term (n = 161, 4 RCTs, RR 1.23, CI 0.76 to 1.99, low quality evidence) nor with numbers of people requiring anticholinergic medication at short/medium term (n = 102, 3 RCTs, RR 1.38, CI 0.75 to 2.25, low quality evidence).Three studies in total compared high doses (100 to 200 mg) of flupenthixol decanoate with the standard doses ( 40mg) per injection. Two trials found relapse at medium term (n = 18, 1 RCT, RR 1.00, CI 0.27 to 3.69, low quality evidence) to be similar between the groups. However people receiving a high dose had slightly more favourable medium term mental state results on the Brief Psychiatric Rating Scale (BPRS) (n = 18, 1 RCT, MD -10.44, CI -18.70 to -2.18, low quality evidence). There was also no significant difference in the use of anticholinergic medications to deal with side effects at short term (2 RCTs n = 47, RR 1.12, CI 0.83 to 1.52 very low quality evidence). One trial comparing a very low dose of flupenthixol decanoate ( 6 mg) with a low dose ( 9 mg) per injection reported no difference in relapse rates (n = 59, 1 RCT, RR 0.34, CI 0.10 to 1.15, low quality evidence). AUTHORS' CONCLUSIONS: In the current state of evidence, there is nothing to choose between flupenthixol decanoate and other depot antipsychotics. From the data reported in clinical trials, it would be understandable to offer standard dose rather than the high dose depot flupenthixol as there is no difference in relapse. However, data reported are of low or very low quality and this review highlights the need for large, well-designed and reported randomised clinical trials to address the effects of flupenthixol decanoate.

beplay体育安全吗DrugBank数据引用了这篇文章

药物

Flupentixol

药物靶点

药物	目标	类	生物	药理作用	行动
Flupentixol	5 -羟色胺受体2摄氏度	蛋白质	人类	未知的	拮抗剂	细节
Flupentixol	Alpha-1A肾上腺素能受体	蛋白质	人类	未知的	拮抗剂	细节
Flupentixol	多巴胺D3受体	蛋白质	人类	未知的	拮抗剂	细节
Flupentixol	多巴胺D4受体	蛋白质	人类	未知的	拮抗剂	细节